MTOR and hepatocellular carcinoma: To determine whether PGRN-mediated mTOR signaling is involved in the oncogenic role IL-6 in HCC, a rescue study was performed by persistent activation of mTOR signaling in IL-6-treated HepG2 cells transfected with control or specific PGRN siRNA.